Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574292 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TDP1KDM4ETSHRMAPK1 | |
| SCHEMBL25118322 | 0.80 | TSHR (0.42) | ALDH1A1TDP1KDM4ETSHRMAPK1 | |
| SCHEMBL1359660 | 0.80 | TSHR (0.42) | ALDH1A1TDP1KDM4ETSHRMAPK1 | |
| SCHEMBL5313141 | 0.78 | CYP3A4 (0.46) | ALDH1A1TDP1KDM4ETSHRMAPK1 | |
| SCHEMBL24265413 | 0.78 | TRPV1 (0.43) | ALDH1A1TDP1KDM4ETSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL27555401 | 0.77 | HSD17B10 (0.44) | ALDH1A1TDP1KDM4ETSHRMAPK1 | |
| SCHEMBL5671151 | 0.77 | MAOB (0.59) | CYP3A4PTPRZ1 | |
| SCHEMBL25416404 | 0.76 | KDM4E (0.41) | ALDH1A1TDP1KDM4ETSHRMAPK1 | |
| SCHEMBL514154 | 0.76 | KDM4E (0.41) | ALDH1A1TDP1KDM4ETSHRMAPK1 | |
| SCHEMBL9680787 | 0.75 | KDM4E (0.52) | ALDH1A1TDP1KDM4ETSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10991972-B2 | Electrolyte solution, positive electrode, and lithium-ion battery comprising the electrolyte solution and/or the positive electrode | BYD COMPANY LIMITED (CN) | 2021-04-27 | — | — | US | claimed |
| US-20190036156-A1 | ELECTROLYTE SOLUTION, POSITIVE ELECTRODE, AND LITHIUM-ION BATTERY COMPRISING THE ELECTROLYTE SOLUTION AND/OR THE POSITIVE ELECTRODE | BYD COMPANY LIMITED (CN) | 2019-01-31 | — | — | US | claimed |
| EP-3407416-A1 | ELECTROLYTIC SOLUTION, POSITIVE ELECTRODE, AND LITHIUM-ION BATTERY CONTAINING THE ELECTROLYTIC SOLUTION AND/OR THE POSITIVE ELECTRODE | BYD Company Limited (CN) | 2018-11-28 | — | — | EP | claimed |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | claimed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| EP-1917246-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | claimed |
| WO-2007020046-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | claimed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | claimed |
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260047580-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2026-02-19 | — | — | US | disclosed |
| EP-4661964-A1 | COMPOUNDS AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| US-12478067-B2 | Heterocyclic compound and harmful arthropod pest control composition containing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-11-25 | — | — | US | disclosed |
| US-20250353859-A1 | COMPOUNDS AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-0000156-B1 | 2-ARYLAMINO-3,5-DINITRO-BENZOTRIFLUORIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS PESTICIDES. | BAYER AG (DE) | 1980-11-12 | — | — | EP | disclosed |
| EP-0010420-A1 | Pyridyl-substituted thiazolidine and 1,3-thiazine derivatives, processes for their preparation, agricultural compositions containing said derivatives and methods for regulating plant growth and protecting plants from fungi | ELI LILLY AND COMPANY (US) | 1980-04-30 | — | — | EP | disclosed |
| EP-0000156-A1 | 2-Arylamino-3,5-dinitro-benzotrifluorides, process for their preparation and their use as pesticides. | BAYER AG (DE) | 1979-01-10 | — | — | EP | disclosed |
| US-4031094-A | ANOREXIGEN AND ANXIOLYTIC AGENTS | SYNTHELABO (FR) | 1977-06-21 | — | — | US | disclosed |
| US-3954763-A | N-Metatrifluoromethylthiophenyl-piperazine | SYNTHELABO (FR) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | ALDH1A1 899/4885TDP1 4073/4885KDM4E 2679/4885 |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | CACNA1A, BMP4, TPX2 | ALDH1A1 3966/4885TDP1 2316/4885KDM4E 274/4885 |
| US-12478067-B2 | Heterocyclic compound and harmful arthropod pest control composition containing same | C5, COX6C, C1S | ALDH1A1 1268/4885TDP1 4362/4885KDM4E 1825/4885 |
| US-20260047580-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME | COX6C, COX6B1, CYC1 | ALDH1A1 1905/4885TDP1 4277/4885KDM4E 2265/4885 |
| US-20250353859-A1 | COMPOUNDS AS CCR6 INHIBITORS | CCR6, CCR4, CCR1 | ALDH1A1 3366/4885TDP1 2592/4885KDM4E 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.